Algae Life Sciences announced today that it has successfully petitioned FDA for a New Dietary Ingredients (NDI) notification for its astaxanthin ingredient.
Algae Life Sciences (Irvine, CA) announced today that it has successfully petitioned FDA for a New Dietary Ingredients (NDI) notification for its flagship astaxanthin line, AstaZine. The ingredients are derived from algae species Haematococcus pluvialis.
The news comes a little over a month since ingredients supplier Beijing Gingko Group (BGG; Beijing) announced it would be spinning off its algae nutrition ingredients into Algae Life Sciences, a new subsidiary for BGG.
“We are happy to have received a letter of acknowledgement without objection from FDA for our flagship product, AstaZine natural astaxanthin, which is derived from microalgae that we carefully cultivate in fully closed glass tube photobioreactors (PBRs) free from contamination,” said Joe Huff, CEO of AlgaeLife’s operations based in the United States.
AstaZine is available in range of forms, including 2% water-soluble powder, organic-certified 5% powder, 2.0% and 2.5% microencapsulated beadlets, and 5%, 10%, and 20% oleoresin.
“Although we are not the first company to receive an NDI notification for natural astaxanthin, this NDI reinforces our commitment to provide the supplement industry with high-quality ingredients that you can trust,” added Huff.
Nutritional Outlook Magazine